Lorne Steinberg Wealth Management Inc. Has $4.71 Million Stock Position in Becton, Dickinson and Company $BDX

Lorne Steinberg Wealth Management Inc. lowered its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.7% in the second quarter, HoldingsChannel reports. The firm owned 27,313 shares of the medical instruments supplier’s stock after selling 480 shares during the period. Lorne Steinberg Wealth Management Inc.’s holdings in Becton, Dickinson and Company were worth $4,705,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Saudi Central Bank acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth about $26,000. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth about $27,000. Alpine Bank Wealth Management acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth about $29,000. Cornerstone Planning Group LLC increased its position in shares of Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 99 shares in the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth about $31,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Activity

In other news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders have sold 1,838 shares of company stock valued at $348,392. 0.36% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages recently issued reports on BDX. Piper Sandler reiterated a “neutral” rating and set a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Argus raised their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Royal Bank Of Canada restated a “sector perform” rating and issued a $211.00 price objective on shares of Becton, Dickinson and Company in a research report on Thursday. Morgan Stanley raised their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $205.40.

Becton, Dickinson and Company Stock Up 2.1%

Shares of NYSE BDX opened at $189.20 on Monday. The firm has a market capitalization of $54.23 billion, a PE ratio of 34.03, a price-to-earnings-growth ratio of 1.48 and a beta of 0.25. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The firm’s 50-day moving average is $190.60 and its 200-day moving average is $184.37.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The company had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were paid a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 74.82%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.